Morgan Stanley Increases Insmed (NASDAQ:INSM) Price Target to $102.00

Insmed (NASDAQ:INSMGet Free Report) had its price objective lifted by stock analysts at Morgan Stanley from $90.00 to $102.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price suggests a potential upside of 5.28% from the stock’s previous close.

Several other research firms also recently weighed in on INSM. Guggenheim reissued a “buy” rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. Citigroup upgraded shares of Insmed to a “buy” rating in a research report on Tuesday. Stifel Nicolaus lowered their price objective on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. Wells Fargo & Company lifted their price objective on shares of Insmed from $107.00 to $119.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $104.81.

View Our Latest Stock Analysis on Insmed

Insmed Trading Down 1.1%

INSM opened at $96.88 on Wednesday. Insmed has a 12 month low of $60.40 and a 12 month high of $100.00. The business has a fifty day moving average price of $70.73 and a 200 day moving average price of $73.47. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market capitalization of $17.65 billion, a price-to-earnings ratio of -17.33 and a beta of 0.80.

Insmed (NASDAQ:INSMGet Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million for the quarter, compared to analysts’ expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period last year, the firm earned ($1.06) earnings per share. Sell-side analysts expect that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 4,999 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $67.81, for a total value of $338,982.19. Following the sale, the insider now directly owns 115,879 shares of the company’s stock, valued at approximately $7,857,754.99. This represents a 4.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Michael Alexander Smith sold 409 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $65.61, for a total transaction of $26,834.49. Following the completion of the sale, the insider now owns 91,794 shares in the company, valued at $6,022,604.34. This represents a 0.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 262,166 shares of company stock valued at $20,585,587. 3.00% of the stock is owned by corporate insiders.

Institutional Trading of Insmed

Hedge funds and other institutional investors have recently bought and sold shares of the company. National Bank of Canada FI boosted its holdings in Insmed by 9.7% in the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 147 shares during the last quarter. M&T Bank Corp grew its stake in Insmed by 4.7% during the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company’s stock valued at $252,000 after purchasing an additional 147 shares in the last quarter. Snowden Capital Advisors LLC grew its position in shares of Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock worth $456,000 after buying an additional 158 shares in the last quarter. Steward Partners Investment Advisory LLC increased its position in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Insmed by 3.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company’s stock valued at $446,000 after buying an additional 186 shares during the last quarter.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Articles

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.